Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Drug development

Topic: Brain proteins, microglia and lab models

Plain-language summary

The interventions in all the recommendation statements were compared to no treatment. (STRONG). 5 We suggest that clinicians use armodafinil for the treatment of narcolepsy in adults. (CONDITIONAL). 6 We suggest that clinicians use dextroamphetamine for the treatment of narcolepsy in adults. (CONDITIONAL). 7 We suggest that clinicians use methylphenidate for the treatment of narcolepsy in adults. (STRONG). 9 We suggest that clinicians use clarithromycin for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 10 We suggest that clinicians use methylphenidate for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 11 We suggest that clinicians use pitolisant for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL). 12 We suggest that clinicians use sodium oxybate for the treatment of idiopathic hypersomnia in adults. Adult patients with kleine-levin syndrome 13 We suggest that clinicians use lithium for the treatment of Kleine-Levin syndrome in adults. Adult patients with hypersomnia due to medical conditions Hypersomnia secondary to alpha-synucleinopathies 14 We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to dementia with Lewy bodies in adults. (CONDITIONAL). 15 We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to Parkinson's disease in adults. (CONDITIONAL). 16 We suggest that clinicians use sodium oxybate for the treatment of hypersomnia secondary to Parkinson's disease in adults. Posttraumatic hypersomnia 17 We suggest that clinicians use armodafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. (CONDITIONAL). 18 We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to traumatic brain injury in adults. Adult patients with genetic disorders associated with primary central nervous system somnolence 19 We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to myotonic dystrophy in adults. Adult patients with hypersomnia secondary to brain tumors, infections, or other central nervous system lesions 20 We suggest that clinicians use modafinil for the treatment of hypersomnia secondary to multiple sclerosis in adults. Pediatric patients with narcolepsy 21 We suggest that clinicians use modafinil for the treatment of narcolepsy in pediatric patients. (CONDITIONAL). 22 We suggest that clinicians use sodium oxybate for the treatment of narcolepsy in pediatric p

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Maski, K., Trotti, L. M., Kotagal, S., Robert Auger, R., Rowley, J. A., Hashmi, S. D., et al. (2021). Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. https://doi.org/10.5664/jcsm.9328

Vancouver

Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2021. doi:10.5664/jcsm.9328. PMID: 34743789.

BibTeX

@article{maski2021-34743789,
  author  = {Maski, K. and Trotti, L. M. and Kotagal, S. and Robert Auger, R. and Rowley, J. A. and Hashmi, S. D. and Watson, N. F.},
  title   = {{Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline}},
  journal = {Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine},
  year    = {2021},
  doi     = {10.5664/jcsm.9328},
  pmid    = {34743789},
  url     = {https://doi.org/10.5664/jcsm.9328}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 67/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 0 of 2. 39 of the 58 points it could be judged on, which is 67 of 100. Total 67 of 100.39 of the 58 points we could judge = 67 of 100

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 39 of the 58 points we could judge it on, which is 67 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34743789)
Free to read 0 / 2 Behind a paywall — scores zero
Points 39 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 39 of the 58 points we could judge it on is 67 out of 100.
Total 67 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also tagged “clinical-practice”

8 studies in the library carry the topic tag “clinical-practice”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 8 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →